Literature DB >> 19440000

RNA interference-mediated silencing of the phosphatidylinositol 3-kinase catalytic subunit attenuates growth of human ovarian cancer cells in vitroand in vivo.

Xi Zhang1, Hong-Xin Deng, Xia Zhao, Dan Su, Xian-Chen Chen, Li-Juan Chen, Yu-Quan Wei, Qian Zhong, Zheng-Yu Li, Xiang He, Tao Yi.   

Abstract

OBJECTIVE: The phosphatidylinositol 3-kinase (PI3K) pathway plays a critical role in ovarian cancer cell survival and proliferation. The aim of this study was to determine whether the suppression of the PI3K catalytic subunit p110alphainhibits the growth of ovarian cancer cells in vitro and in vivo.
METHODS: The short hairpin RNA (shRNA) was used to knock down the expression of p110alpha in SKOV3 human ovarian cancer cells. The effects of shRNA on cell viability and apoptosis in vitro were assessed using the MTT assay and flow-cytometric analysis. Furthermore, the growth inhibition capacity of shRNA on ovarian carcinoma xenografts was tested in nude mice. Tumor cell proliferation, apoptosis and angiogenesis were measured by proliferating cell nuclear antigen, TUNEL and CD31 immunohistochemistry, respectively.
RESULTS: Using sequence-specific shRNA, we have silenced the expression of p110alpha in SKOV3 cells. shRNA-mediated knockdown of p110alpha correlated in vitro with decreased cell viability and increased apoptosis. Furthermore, inhibition of p110alpha significantly delayed the growth of ovarian carcinoma xenografts, and ultimately resulted in decreased cell proliferation, induction of apoptosis as well as a reduction in microvessel density.
CONCLUSIONS: Our findings suggest that shRNA-directed targeting of p110alpharaises the potential of its application in human ovarian cancer therapy. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19440000     DOI: 10.1159/000218201

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  6 in total

1.  Begin with a text: teaching the poetics of medicine.

Authors:  Catherine Belling
Journal:  J Med Humanit       Date:  2013-12

2.  Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.

Authors:  Jia Huang; Lin Zhang; Joel Greshock; Theresa A Colligon; Yan Wang; Renee Ward; Dionyssios Katsaros; Heini Lassus; Ralf Butzow; Andrew K Godwin; Joseph R Testa; Katherine L Nathanson; Phyllis A Gimotty; George Coukos; Barbara L Weber; Yan Degenhardt
Journal:  Genes Chromosomes Cancer       Date:  2011-05-11       Impact factor: 5.006

3.  Efficient inhibition of lung cancer in murine model by plasmid-encoding VEGF short hairpin RNA in combination with low-dose DDP.

Authors:  Yong P Ma; Yang Yang; Shuang Zhang; Xiang Chen; Na Zhang; Wei Wang; Zhi X Cao; Yu Jiang; Xia Zhao; Yu Q Wei; Hong X Deng
Journal:  J Exp Clin Cancer Res       Date:  2010-05-25

4.  Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.

Authors:  Carmela De Marco; Nicola Rinaldo; Paola Bruni; Carmine Malzoni; Fulvio Zullo; Fernanda Fabiani; Simona Losito; Marianna Scrima; Federica Zito Marino; Renato Franco; Alfina Quintiero; Valter Agosti; Giuseppe Viglietto
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

5.  Anticancer properties and mechanisms of fucoidan on mouse breast cancer in vitro and in vivo.

Authors:  Meilan Xue; Yinlin Ge; Jinyu Zhang; Qing Wang; Lin Hou; Yongchao Liu; Lingling Sun; Quan Li
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

6.  PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.

Authors:  R L Ross; H R McPherson; L Kettlewell; S D Shnyder; C D Hurst; O Alder; M A Knowles
Journal:  BMC Cancer       Date:  2016-07-28       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.